Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) following
induction chemotherapy. However, a large majority subsequently relapse and succumb to the
disease. Currently, cytogenetics and molecular aberrations are the best prognostic
indicators; however, these factors cannot prognosticate accurately for individual patients.
Overall, the majority of patients with favorable or intermediate-risk AML will experience
relapse. Prognosis after relapse is dismal with a five-year overall survival rate of less
than 10%. A leukemia stem cell (LSC) paradigm may explain this failure of CR to reliably
translate into cure. This study is undertaken to determine whether the presence of LSCs has
prognostic value as well as to determine whether the presence of LSCs has predictive value.
This study has an observational component, whereby we intent evaluate whether the presence or
absence of LSCs is prognostic. This study also has an interventional component in which it
uses LSC status to determine whether favorable and intermediate risk AML patients in CR
receive consolidation with chemotherapy or allogeneic HCT.